Our Pricing

Switch to Wegovy: Buy at Cured Pharmacy with Expert Guidance

Published on: June 03, 2026

Thinking about making the switch to Wegovy UK online? At Cured Pharmacy, we've supported thousands of patients transitioning from other weight loss treatments to Wegovy (semaglutide) with transparent pricing from £79.00, expert clinical guidance, and discreet next-day delivery across the UK. Our UK-registered prescribers assess your current treatment, medical history, and weight loss goals to ensure a safe, effective transition tailored to your needs.

Why Patients Are Switching to Wegovy in 2025

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1 to regulate appetite and food intake [1]. Originally developed for type 2 diabetes management, semaglutide has demonstrated remarkable efficacy for weight management in clinical trials, leading to its MHRA approval specifically for chronic weight management in the UK.

The STEP 1 trial showed participants using Wegovy achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. This evidence base, combined with once-weekly dosing convenience and improved tolerability profiles compared to daily injectable alternatives, has made Wegovy the preferred choice for many UK patients and prescribers alike.

Patients switching from daily liraglutide injections (Saxenda) often report the once-weekly Wegovy regimen fits more seamlessly into their lifestyle, whilst those transitioning from oral treatments like Orlistat appreciate the superior weight loss outcomes observed in head-to-head comparisons. Our superintendent pharmacist Tarun Kumar notes that transparent pricing and consistent UK supply have also driven increased demand for Wegovy throughout 2025.

Switching from Saxenda to Wegovy: What to Expect

If you're currently using Saxenda (liraglutide 3mg daily injection), switching to Wegovy requires clinical assessment by a UK prescriber to determine the appropriate starting dose and transition timeline. Most patients begin Wegovy at the 0.25mg weekly dose regardless of their previous Saxenda dose, allowing the body to adjust to the new medication gradually [2].

Your prescriber will typically recommend stopping Saxenda and starting Wegovy on the same day, though some patients prefer a brief washout period. The initial four weeks on Wegovy 0.25mg serve as a tolerance-building phase before dose escalation begins. Common side effects during transition include mild nausea, which usually improves within the first fortnight as your body adapts to semaglutide.

Clinical data suggests patients switching from liraglutide to semaglutide may experience additional weight loss, with the STEP 8 trial demonstrating semaglutide's superior efficacy compared to liraglutide in direct comparison [3]. At Cured Pharmacy, our prescribers provide detailed switching guidance and ongoing support throughout your dose escalation journey, ensuring you achieve optimal results whilst minimising side effects.

Managing Side Effects During the Switch

Gastrointestinal side effects are the most commonly reported during the transition to Wegovy, particularly during the first month. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can significantly reduce nausea and digestive discomfort. If side effects persist beyond two weeks or become severe, contact your prescriber immediately — dose adjustments or additional antiemetic support may be appropriate.

Switching from Ozempic to Wegovy: Understanding the Difference

Ozempic and Wegovy both contain semaglutide, but they're licensed for different indications and available in different dose strengths. Ozempic is licensed specifically for type 2 diabetes management, whilst Wegovy is licensed for chronic weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities [4].

The maximum maintenance dose differs significantly: Ozempic reaches 2mg weekly for diabetes control, whilst Wegovy escalates to 2.4mg weekly for weight management — the dose demonstrated most effective in the STEP trial programme [1]. If you've been using Ozempic off-label for weight loss, switching to Wegovy ensures you're receiving the MHRA-approved treatment at the clinically validated dose for your indication.

At Cured Pharmacy, your UK prescriber will review your current Ozempic dose and determine the appropriate Wegovy starting point. Some patients may begin at a higher dose than the standard 0.25mg if they're already tolerating Ozempic 1mg or 2mg weekly, though this decision is made individually based on your treatment response and side effect profile. All switches require clinical assessment to ensure safety and regulatory compliance.

How to Switch to Wegovy UK Online at Cured Pharmacy

Switching to Wegovy at Cured Pharmacy takes under three minutes through our streamlined online consultation process. You'll complete a clinical questionnaire covering your current weight loss treatment, medical history, weight loss goals, and any medications you're taking. Our UK-registered prescribers review every consultation individually — there are no automated approvals.

If Wegovy is clinically appropriate for you, your prescriber will issue an NHS-valid prescription and our pharmacy team dispenses genuine UK-licensed Wegovy pens the same day. We offer discreet next-day delivery across the UK in plain, unmarked packaging. Your first delivery includes full patient information leaflets, injection technique guidance, and sharps disposal advice.

Pricing is transparent from the start: Wegovy costs from £79.00 at Cured Pharmacy, with the exact price depending on your prescribed dose. There are no hidden consultation fees, and you'll see the total cost before completing your assessment. Our lowest price guarantee ensures you're getting the most competitive Wegovy pricing available from any UK-registered online pharmacy.

Ongoing Prescriber Support

Weight management is a long-term commitment, and our clinical team remains available throughout your Wegovy journey. Monthly follow-up consultations track your progress, manage any side effects, and adjust dosing as you escalate toward the 2.4mg maintenance dose. You can contact our prescribers between consultations if questions or concerns arise — expert support is included in your treatment cost.

Wegovy Dosing Schedule: What Happens After You Switch

Wegovy follows a structured dose escalation schedule designed to optimise weight loss whilst minimising gastrointestinal side effects. Most patients begin at 0.25mg weekly for four weeks, then increase to 0.5mg weekly for four weeks, followed by 1mg weekly, 1.7mg weekly, and finally the 2.4mg maintenance dose [2].

Each dose increase occurs monthly, allowing your body time to adapt to higher semaglutide levels. Your prescriber may recommend staying at a lower dose longer if you're experiencing significant side effects or achieving excellent weight loss results at your current dose. The goal is sustainable, healthy weight reduction — not rushing to the maximum dose.

Clinical trials show the greatest weight loss occurs at the 2.4mg maintenance dose, with participants losing an average 14.9% of their baseline body weight over 68 weeks [1]. However, individual responses vary, and some patients achieve their weight loss goals at lower doses. Your UK prescriber will work with you to find the optimal dose that balances efficacy with tolerability for your specific circumstances.

Is Switching to Wegovy Right for You?

Wegovy may be clinically appropriate if you have a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [4]. It's particularly suitable for patients who haven't achieved sufficient weight loss with lifestyle modifications alone, or those seeking to transition from less effective or less convenient weight management treatments.

Wegovy is not suitable for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pregnancy or planned pregnancy, and severe gastrointestinal disease. Your prescriber will assess your full medical history during consultation to ensure Wegovy is safe and appropriate for you.

At Cured Pharmacy, we're committed to responsible prescribing. If Wegovy isn't clinically suitable based on your consultation responses, our prescribers will explain why and discuss alternative options that may better meet your needs. Our clinical team includes superintendent pharmacist Tarun Kumar (GPhC 2233073), and all prescribing decisions align with MHRA guidance and NICE recommendations for weight management in adults.

Combining Wegovy with Lifestyle Changes

Wegovy is most effective when combined with a reduced-calorie diet and increased physical activity. Clinical trial participants received lifestyle intervention support alongside semaglutide, and this combined approach produced the weight loss outcomes observed in published data [1]. Your prescriber can provide guidance on sustainable dietary changes and exercise programmes that complement your Wegovy treatment for optimal long-term results.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy 2.4 mg Solution for Injection in Pre-filled Pen: Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Rubino, D. M., Greenway, F. L., Khalid, U., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619 [accessed 13 August 2026]
4. National Institute for Health and Care Excellence. (2023). Semaglutide for Managing Overweight and Obesity: Technology Appraisal Guidance [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or switching between weight loss treatments.